Eli Lilly (LLY)Sen. Sheldon Whitehouse disclosed a purchase $15K–$50K

$15,001–$50,000

Reported range · official band, not an exact amount

8 days

Disclosure lag

Traded

Oct 30, 2024

Disclosed

Nov 7, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 13, 2024FDAFDA drug approval: Ebglyss
2. Sep 27, 2024FDAFDA drug approval: Retevmo
3. Sep 27, 2024FDAFDA drug approval: Retevmo
4. Sep 27, 2024FDAFDA drug approval: Retevmo
5. Sep 27, 2024FDAFDA drug approval: Retevmo
6. Oct 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
7. Oct 18, 2024FDAFDA drug approval: Zepbound
8. Oct 30, 2024 · this disclosureCongressDisclosed purchase of LLY — reported range $15,001 - $50,000

What came next

1. Nov 8, 2024InsiderOfficer sold ~$723K of LLY shares in the open market
2. Nov 8, 2024CongressDisclosed sale of LLY — reported range $15,001 - $50,000
3. Nov 13, 2024FDAFDA drug approval: Verzenio
4. Nov 14, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
5. Nov 19, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
6. Dec 9, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
7. Dec 10, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
8. Dec 11, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
9. Dec 12, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
10. Dec 13, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
11. Dec 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
12. Dec 18, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
13. Dec 20, 2024FDAFDA drug approval: Zepbound
14. Dec 24, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
15. Jan 8, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
16. Jan 15, 2025FDAFDA drug approval: Omvoh
17. Jan 15, 2025FDAFDA drug approval: Omvoh
18. Jan 21, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
19. Jan 22, 2025CongressDisclosed purchase of LLY — reported range $50,001 - $100,000
20. Jan 27, 2025FDAFDA drug approval: Cyramza

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Sen. Sheldon Whitehouse

• Senate eFD periodic transaction report at JPMorgan Chase (JPM)Oct 1, 2026
• Senate eFD periodic transaction report at Analog Devices (ADI)Oct 1, 2026
• Senate eFD periodic transaction report at Visa (V)Oct 1, 2026
• Senate eFD periodic transaction report at Visa (V)Oct 1, 2026
• Senate eFD periodic transaction report at JPMorgan Chase (JPM)Oct 1, 2026

The full history of Sen. Sheldon Whitehouse is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Eli Lilly

• SEC Form 144Oct 7, 2026
• USAspending.gov award recordSep 1, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 18, 2026

Everything OQRO holds on this company is on its LLY page.